Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Preeclampsia (CRUSH)
NCT04725812Phase 2Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in preeclampsia, sponsored by Cedars-Sinai Medical Center. Started Sep 2021; status: terminated.
02
Drugs
eculizumab
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT04725812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725812.